{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000110","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.736002+00:00","generated_at":"2026-05-17T06:38:58.924807+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Serina Therapeutics enters up to $20M convertible note from director Gregory H. Bailey for clinical study SER-252-1b","bullets":["Up to $20M drawn in 5 tranches tied to milestones for SER-252-1b registrational study; $5M available by Sept 30, 2025.","10% annual interest; conversion at $5.18/share; warrants at $5.44/share for 100% of conversion shares.","Lender is Dr. Gregory H. Bailey, board member and affiliate of largest shareholder Juvenescence; approved by independent special committee.","Senior unsecured; prepayable at any time without penalty; mandatory repayment on change of control or liquidity event.","Maturity 5 years from initial funding; customary events of default with 2% default interest."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000110","json":"https://secwatch.observer/filing/0001708599-25-000110.json","markdown":"https://secwatch.observer/filing/0001708599-25-000110.md","text":"https://secwatch.observer/filing/0001708599-25-000110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/0001708599-25-000110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/ser-20250909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:38:58.924807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76754fdbb330ee064eae7dd13ab389ff1085302f","claim":"Serina Therapeutics, Inc. incurred convertible notes of up to $20 million with Gregory H. Bailey, M.D. at annual rate of 10% maturing five years after the initial funding date.","evidence_excerpt":"On September 9, 2025, Serina Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an unsecured convertible note (the “Convertible Note”) with Gregory H. Bailey, M.D., a member of the Company’s Board of Directors, making available to the Company an aggregate principal amount of up to $20 million.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/0001708599-25-000110-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"up to $20 million"},{"label":"Counterparty","value":"Gregory H. Bailey, M.D."},{"label":"Rate","value":"annual rate of 10%"},{"label":"Maturity","value":"five years after the initial funding date"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"69f6be33e55651bd516db3ac5b281d1008a99062","claim":"Serina Therapeutics, Inc. issued convertible note to Gregory H. Bailey, M.D. for aggregate principal amount of up to $20 million.","evidence_excerpt":"note (the “Convertible Note”) with Gregory H. Bailey, M.D., a member of the Company’s Board of Directors, making available to the Company an aggregate principal amount of up to $20 million. Under the Convertible Note, borrowings may be drawn in the discretion of the Company in five tranches tied to certain clinical and operational milestones, provided that if at","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/0001708599-25-000110-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"convertible note"},{"label":"Purchaser","value":"Gregory H. Bailey, M.D."},{"label":"Consideration","value":"aggregate principal amount of up to $20 million"}],"fact_type":"equity_issuance"},{"claim_id":"d9e755a6edfeedc83657af1573b3ccbc3a71f99a","claim":"Serina Therapeutics, Inc. issued 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date of warrant to Gregory H. Bailey, M.D. for exercise price equal to $5.44 per share.","evidence_excerpt":"equal to 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date. Such warrants will have an exercise price equal to $5.44 per share. The warrants expire on the earlier of sixty days following the achievement of Milestone 5 or September 30, 2026, unless stockholder approval has not been obtained as","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/0001708599-25-000110-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date"},{"label":"Purchaser","value":"Gregory H. Bailey, M.D."},{"label":"Consideration","value":"exercise price equal to $5.44 per share"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}